China Myocardial Infarction Market to Reach $1,066.0 Million by 2035

China myocardial infarction market was valued at $776.0 million in 2025 and is projected to reach $1,066.0 million by 2035, growing at a CAGR of 8.90% during the forecast period (2026–2035). Market growth is primarily driven by the increasing burden of cardiovascular diseases and the rising adoption of advanced interventional and diagnostic medical devices. According to the World Health Organization (WHO), cardiovascular diseases remain the leading cause of death globally, accounting for nearly 17.9 million casualties annually, representing approximately 32% of total global mortality. In China, the growing prevalence of hypertension, diabetes, and aging population is significantly increasing hospital admissions for myocardial infarction. This rising disease burden is accelerating the demand for advanced cardiac devices such as pacemakers, implantable cardioverter defibrillators, and catheter-based interventions across hospitals and specialty centers.

Browse the full report description of “China Myocardial Infarction Market Size, Share & Trends Analysis Report by Treatment Type (Pharmacological Treatment, Interventional Procedures, Adjunct & Supportive Care), by Medical Device Type (Left Ventricular Assist Device, Pacemaker, Catheters, Implantable Cardioverter Defibrillator, Others), by End-User (Hospitals, Specialty Centres, ASCs), and Forecast Period (2026–2035)” at https://www.omrglobal.com/industry-reports/china-myocardial-infarction-market

Innovation Leaders Transforming the Myocardial Infarction Market

The key players in the china myocardial infarction market include top companies such as Johnson & Johnson, Abbott, Medtronic, Siemens Healthineers, and GE HealthCare, among others. The market is witnessing strong growth due to increasing adoption of minimally invasive interventional procedures and technological advancements in cardiac care devices. Hospitals dominate the end-user segment due to the availability of advanced infrastructure, skilled cardiologists, and rising emergency cardiac care cases. Additionally, the integration of AI-based imaging and real-time monitoring systems is improving early diagnosis and treatment outcomes.

• In March 2026, Medtronic reported results from its ALERT trial showing that AI-enabled clinician alerts improved evaluation and treatment of cardiovascular conditions, leading to a 40% increase in valve interventions and a 27% rise in specialist evaluations. The study demonstrated that automated electronic health record alerts enhanced early diagnosis and accelerated clinical decision-making in cardiac care. These advancements highlight the growing role of AI-driven technologies in improving cardiovascular treatment pathways, indirectly supporting myocardial infarction management.

• In November 2025, Siemens Healthineers launched AI-enabled radiology services designed to streamline imaging workflows from scheduling to reporting, enhancing diagnostic efficiency and reducing radiologist workload. The solution enables faster image analysis with up to 25% improved annotation speed while maintaining clinical accuracy. Such advancements in AI-powered imaging support early detection of cardiovascular conditions, indirectly strengthening myocardial infarction diagnosis and treatment pathways.

Market Coverage

• The market number available for – 2025–2035
• Base year- 2025
• Forecast period- 2026–2035
• Segment Covered-
• By Treatment Type
• By Medical Device Type
• By End-User
• Competitive Landscape: Johnson & Johnson, Abbott, Medtronic, Siemens Healthineers, GE HealthCare, among others.

Key questions addressed by the report

• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• Who is the leader in the market?
• How are players addressing challenges to sustain growth?
• Where is the investment opportunity?

China Myocardial Infarction Market Report Segment

By Treatment Type

• Pharmacological Treatment
• Interventional Procedures
• Adjunct & Supportive Care

By Medical Device Type

• Left Ventricular Assist Device
• Pacemaker
• Catheters
• Implantable Cardioverter Defibrillator
• Others

By End-User

• Hospitals
• Specialty Centres
• ASCs

To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/china-myocardial-infarction-market